This technology is an immunosuppressant that suppresses T cell proliferation and can be used to treat organ transplant rejection and autoimmune or inflammatory conditions.
T cell proliferation can cause complications with organ transplantation and contribute to autoimmune and inflammatory disease pathology. The immunosuppressant market is growing rapidly, and there is ongoing need for therapeutics that demonstrate long-term slowing of disease progression.
This technology is an enzyme that suppresses T cell proliferation through mechanisms independent of its catalytic domain. This immunosuppressive effect is observed in mixed lymphocyte reaction in vitro, while mice lacking this protein experience enhanced T cell proliferation. This technology could be used to suppress T cell expansion in autoimmune or inflammatory conditions and in prevention of transplant rejection.
IR 20031, 14018, 22097
Licensing Contact: Jerry Kokoshka